Shares of Zoetis have been roughly average performers over the past decade. The shares seem appealingly valued at recent ...

Zoetis Inc. (NYSE:ZTS) today announced that it has agreed to sell $1.850 billion of senior notes, consisting of $850.0 ...

Zoetis raised annual forecast and beat second-quarter estimates on Tuesday, driven by strong demand for its medicines and ...

Q2 2025 Management View Kristin C. Peck, CEO, reported "strong broad-based 8% organic operational revenue growth" and noted ...

Meanwhile, the company has an impeccable dividend program. The company has increased its payouts by 502% over the past decade ...

Shares of Zoetis Inc. ZTS slipped 1.46% to $148.81 Wednesday, on what proved to be an all-around grim trading session for the ...

Shares of Zoetis Inc. ZTS rallied 1.09% to $147.38 Friday, on what proved to be an all-around dismal trading session for the ...

Breed Explorer offers veterinarian-approved, science-backed insights to help current and prospective pet owners make informed ...

(ZTS) on Tuesday reported second-quarter net income of $718 million. The Parsippany, New Jersey-based company said it had profit of $1.

Zoetis, a leading animal health company, has shown impressive growth with a 17.55% CAGR since its IPO. Read why I rate ZTS stock a Buy now.

Zoetis's leadership, scale, and innovation position it well against new competitors. Click here to read more about ZTS stock and why it is a Buy.

Zoetis enjoys enviable financial flexibility, even as leverage ticked up in 2015 to finance the purchase of Pharmaq and Abbott's animal health business. With long-term debt at roughly $5.2 billion ...